About the Authors

Rui-Ru Ji, Heshani de Silva, Jian Cao, Aiqing He, Wenjun Huang, Paul S. Kayne, Isaac M. Neuhaus, Karl-Heinz Ott, Becky Penhallow, Mark I. Cockett, Michael G. Neubauer, Nathan O. Siemers, Petra Ross-Macdonald
Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

Yisheng Jin
Johnson Graduate School of Management, Cornell University, Ithaca, New York, United States of America

Robert E. Bruccoleri
Congenomics, Glastonbury, Connecticut, United States of America

Corresponding Author


Competing Interests

The authors are current and previous employees of Bristol-Myers Squibb, who is the manufacturer of dasatinib (one of the compounds included in the study).

Author Contributions

Performed the experiments: HdS JC AH WH BP. Analyzed the data: RRJ YJ KHO PRM. Contributed reagents/materials/analysis tools: RRJ REB PSK IMN MIC NOS. Wrote the paper: RRJ PRM. Developed the analytical methods described in the manuscript: RRJ. Designed the experiments: HdS. Revised the manuscript: YJ REB KHO NOS. Conceived transcriptional dose response concept: MGN.